Home
Products
Oprozomib (ONX 0912)
| Product Name | Oprozomib (ONX 0912) |
| Price: | Inquiry |
| Catalog No.: | CN00136 |
| CAS No.: | 935888-69-0 |
| Molecular Formula: | C25H32N4O7S |
| Molecular Weight: | 532.61 g/mol |
| Purity: | >=98% |
| Type of Compound: | Alkaloids |
| Physical Desc.: | Powder |
| Source: | |
| Solvent: | Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc. |
| SMILES: | COC[C@@H](C(=O)N[C@H](C(=O)[C@]1(C)OC1)Cc1ccccc1)NC(=O)[C@@H](NC(=O)c1cnc(s1)C)COC |
| Contact us | |
|---|---|
| First Name: | |
| Last Name: | |
| E-mail: | |
| Question: | |
| Description | Oprozomib (ONX 0912; PR047) is an orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM.IC50 value: 36 nM/82 nM(20S proteasome β5/LMP7) [1]Target: 20S proteasomeThe anti-MM activity of Oprozomib is associated with activation of caspase-8, caspase-9, caspase-3, and PARP, as well as inhibition of migration of MM cells and angiogenesis. Oprozomib is demonstrated an absolute bioavailability of up to 39% in rodents and dogs. It is well tolerated with repeated oral administration at doses resulting in >80% proteasome inhibition in most tissues and elicited an antitumor response in multiple human tumor xenograft and mouse syngeneic models. |
| Density | 1.3±0.1 g/cm3 |
| Boiling Point | 849.9±65.0 °C at 760 mmHg |
| Flash Point | 467.8±34.3 °C |
| Exact Mass | 532.199158 |
| PSA | 186.96000 |
| LogP | 2.79 |
| Vapour Pressure | 0.0±3.2 mmHg at 25°C |
| Storage condition | -20℃ |